Remove 2012 Remove DNA Remove Packaging Remove Therapies
article thumbnail

Is Recent Gene Therapy Setback for Duchenne Muscular Dystrophy (DMD) Déjà vu All Over Again?

PLOS: DNA Science

In the final chapter of my 2012 book The Forever Fix: Gene Therapy and the Boy Who Saved It , I predicted that the technology would soon expand well beyond the rare disease world. Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases.

article thumbnail

Article FDA Thank You FDA’s oncology advisory committee to consider MRD as a multiple myeloma endpoint

Agency IQ

Patients frequently receive up to four therapies at once and go through multiple prolonged courses of treatment to keep recurrence and progression at bay. Between 2012 and 2018, the five-year relative survival rate for patients with MM was 57%. More recently, CAR T cell therapies have been approved to treat advanced multiple myeloma.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CRISPR breakthroughs: New solutions for common diseases

Drug Discovery World

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. CRISPR also addresses another limitation in CAR T therapies related to the insufficient quantity and poor quality of autologous T cells.

Disease 246
article thumbnail

Beyond Steel Tanks

Codon

In the case of semaglutide, those cells are Saccharomyces cerevisiae— also known as Baker’s yeast — engineered to secrete a peptide precursor that is later purified, chemically modified, packaged into an injectable or tablet form, and then shipped around the world. Continuing this method may not scale.

article thumbnail

Codon Digest: Hackathon Prize Winners

Codon

Since the last Codon Digest, I’ve published: Reasons to Be Grateful for Biotechnology (with Avadhoot Jadhav) AAV Foundations (Part I) An overview of AAV-based gene therapies, how they get made, and where they go wrong. DNA sequences are designed on a computer, and it takes a dozen or more clicks to change a single nucleotide.

DNA 52
article thumbnail

Codon Digest: Hackathon Prize Winners

Codon

Since the last Codon Digest, I’ve published: Reasons to Be Grateful for Biotechnology (with Avadhoot Jadhav) AAV Foundations (Part I) An overview of AAV-based gene therapies, how they get made, and where they go wrong. DNA sequences are designed on a computer, and it takes a dozen or more clicks to change a single nucleotide.

DNA 52